Sanofi-Aventis: A timeline of biopharma deals

Since Chris Viebacher was tapped as CEO of Sanofi-Aventis in September 2008, the company has inked more than $17 billion in deals. Now, with the latest deal rumored to be in the $20 billion range, we're looking back at Viebacher's deal-saturated reign.

 June 30, 2010
Estimated worth: $635M

Summary: Continuing its global deal-making spree, Sanofi-Aventis forged a deal to buy San Diego-based TargeGen for $75 million down and up to $560 million in milestones based on the success of its small molecule kinase inhibitors for leukemia, lymphoma and other blood diseases. Report

June 25, 2010
Estimated worth: $375M-plus

Summary: The developer secured an undisclosed upfront payment and up to $375 million from Sanofi-Aventis for rights to an experimental diabetes treatment. The two companies will collaborate on MBX-2982, a potent selective orally active GPR119 agonist which has completed three Phase I clinical studies and is currently a Phase II clinical study in patients with Type 2 diabetes. Report

Date: June 4, 2010
Estimated worth: $398M

Summary: Sanofi-Aventis paid for the rights to several of Ascenta Therapeutics' early-stage oral drug candidates. The French biotech gained access to MI-773 and MI-519-64, Ascenta's two most advanced drug candidates, which are expected to begin preclinical development later this year. Report

May 28, 2010
Estimated worth: $48M

Summary: Sanofi owns 51 percent of the joint venture, and as part of the deal bought a 4.66 percent stake in Nichi-iko. The J.V.'s first task was to take over marketing and distribution in Japan for Sanofi's sleep drug Amoban, which brought in sales of €43 million ($53 million) in Japan last year. Report

Date: May 19, 2010
Estimated worth: $130.4M (€105M)

Summary: Sanofi-Aventis unveiled a further push into emerging markets with plans to buy Polish consumer healthcare group Nepentes in a deal valuing it at around €105 million ($130.4 million). Report

Date: May 3, 2010
Estimated worth: $345M

Summary: India's Glenmark got $20 million upfront in the deal, along with royalties and a U.S. co-promotion agreement. Sanofi won marketing rights in North America, Europe and Japan for TRPV3 and GRC 15300, two drugs in a new class of pain remedies. Report

Date: April 8, 2010
Estimated worth: $335M

Summary: The latest deal gave the drug giant the exclusive worldwide license of CureDm's Pancreate, a treatment for Type 1 and Type 2 diabetes. Sanofi has the rights to manufacture, develop and market Pancreate for diabetes in human and veterinary applications. Report

Date: March 9, 2010
Estimated worth: unknown

Summary: By combining the animal health business Merck acquired along with Schering-Plough--Intervet--with Sanofi's now-wholly-owned Merial, the companies created the biggest animal drugs-and-vaccines company in the world. Report

Sanofi-Aventis: A timeline of biopharma deals

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.